Contrast-Enhanced PET/CT for Staging of Pancreatic Cancer
Contrast-enhanced PET/CT appears to be better than non-CE PET/CT in assessing distant metastasis in patients with pancreatic cancer.
Contrast-enhanced (CE) PET/CT provides a more precise assessment of distant metastasis, scalene node metastasis, and peritoneal dissemination in patients with pancreatic cancer, according to a study published in the European Journal of Radiology.
Researchers from Japan sought to clarify the diagnostic impact of CE 18F-fluorodeoxyglucose (FDG)–PET/CT for staging of pancreatic cancer compared to non-CE PET/CT.
Ninety-five patients (age range: 36 to 83) diagnosed with primary pancreatic cancer participated in the study, which took place between April 2006 and November 2009. Two blinded reviewers analyzed the images, and the researchers compared diagnostic accuracy between the non-CE PET/CT and CE PET/CT images.
The results showed that, for T-staging, both modalities correctly diagnosed invasion of the duodenum (20 cases, 21%), mesentery (12 cases, 13%), and retroperitoneum (13 cases, 14%).
“The ROC analyses revealed that the Az values of celiac artery (CA), common hepatic artery (CHA), splenic artery (SV), and superior mesenteric vein (SMV) invasion were significantly higher in the CE PET/CT group for both readers,” wrote the authors.
Contrast-enhanced PET/CT correctly diagnosed nodal metastasis in 38 patients (88%); non-CE PET/CT correctly diagnosed the same metastasis in 45 patients (87%). Diagnostic accuracies of nodal metastasis in two modalities were similar.
Distant metastasis, scalene node metastasis, and peritoneal dissemination were correctly assigned in 39 patients (91%) using CE PET/CT, while the same was found in 42 patients (81%) with non-CE PET/CT. “Diagnostic accuracy of distant metastasis, scalene node metastasis, and peritoneal dissemination with CE PET/CT was significantly higher than that of non-CE PET/CT,” the authors noted.
The authors concluded that using contrast-enhanced PET/CT provided a more precise look at distant metastasis, scalene node metastasis, and peritoneal dissemination in patients with pancreatic cancer.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
